June 23, 2026
News
June 23, 2026
Alex Shneider, Founder and CEO of CureLab Oncology, discusses DNA-based immunotherapies, inflammation-driven cancer biology, intelligent combination therapies, and the emerging science of reprogramming the tumour microenvironment.
June 16, 2026
Dr. Alex Shneider, CEO of Curelab Oncology and the developer of Elenagen joins eHealth Radio and the Health News and Cancer Information Channels to discuss this breakthrough.
April 13, 2026
Dr. Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and Director of Oncology at CureLab Oncology Inc., recently presented new clinical findings at the 27th Congress of the European Society of Gynaecological Oncology (ESGO 2026) in Copenhagen, highlighting a promising therapeutic advance for women with platinum-resistant ovarian cancer (PROC).
March 31, 2026
Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease
February 26, 2026
At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer (PROC); one of the most aggressive and treatment-refractory settings in gynecologic oncology.
February 25, 2026
Alexander Shneider, founder and CEO of CureLab Oncology, Inc. shared a post on LinkedIn: “We are honored to see our recent clinical data featured in EMJ Oncology. For patients with platinum‑resistant ovarian cancer – one of the most challenging diagnoses in oncology – these findings point toward what may become a meaningful paradigm shift.
February 19, 2026
Adding therapy to chemo shown to extend survival in small cancer trial
February 17, 2026
February 17, 2026
In this episode of the Talking Biotech podcast, host Dr. Kevin Folta engages with Dr. Alex Schneider, CEO and founder of CureLab, to discuss innovative approaches to cancer treatment, particularly focusing on the challenges posed by refractory cancers such as triple-negative breast cancer and platinum-resistant ovarian cancer.
September 16, 2021
The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
August 11, 2021
Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
March 15, 2021
Patent registration in Hong Kong paves the way to establishing business operations in PRC
January 22, 2021
Based on a scientifically solid proof of concept in dogs and cats, a licensed international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding and to become profitable within 36 months of raising funds.